Alamar Biosciences ALMR
$26.48 −$2.20 (-7.67%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $26.50 +0.08%
Open$28.25
Prev close$28.68
Day range$26.24 – $28.25
Volume712.6K
Market cap$1.84B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$33.55M+68.5% YoY
Operating profit-$15.14M-92.0% YoY
Net profit-$13.34M-66.8% YoY
Diluted EPS-$0.19-58.0% YoY
Free cash flow-$15.37M+0.6% YoY
Operating cash flow-$14.73M
Revenue, last 7 quarters
Net profit, last 7 quarters
Diluted EPS by quarter
Free cash flow by quarter
Profitability & balance sheet
Gross margin59.3%
Operating margin-42.1%
Net margin-48.2%
Return on equity-18.1%
Return on assets-14.5%
Return on invested capital-16.6%
Current ratio9.49
Liabilities / assets19.7%
Cash & investments$226.59M
Total debt$39.87M
Net cash (debt)$186.72M
Where the revenue comes from
Quarter 2026/Q3
By business line
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $378.03M | $390.98M | $186.45M | $139.99M | $139.99M |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained Earnings | -$216.64M | -$203.30M | -$190.10M | -$168.78M | -$168.78M |
| Gains/Losses Not Affecting Retained Earnings | -$173,000.00 | -$139,000.00 | -$80,000.00 | -$72,000.00 | -$72,000.00 |
| -Gross PPE | $51.48M | $49.16M | $36.14M | $44.97M | $44.97M |
| Capital Stock | $7,000.00 | $7,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| Stockholders' Equity | $303.70M | $312.86M | -$178.07M | -$158.95M | -$158.95M |
| Total Equity | $303.70M | $312.86M | -$178.07M | -$158.95M | -$158.95M |
| Other Non-Current Liabilities | $974,000.00 | $1.03M | $1.20M | $599,000.00 | $599,000.00 |
| Convertible preferred securities | $0.00 | $0.00 | $235.00M | $235.00M | $235.00M |
| Derivative Product Liabilities | $0.00 | $0.00 | $331,000.00 | $247,000.00 | $247,000.00 |
| -Long Term Capital Lease Obligation | $39.87M | $39.18M | $28.98M | $29.56M | $29.56M |
| Long Term Debt and Capital Lease Obligation | $39.87M | $49.13M | $103.95M | $39.37M | $39.37M |
| Total Non-Current Liabilities | $40.84M | $50.16M | $340.47M | $275.22M | $275.22M |
| Goodwill and Other Intangible Assets | $1.44M | $1.61M | $1.84M | $1.99M | $1.99M |
| Current Deferred Liabilities | $1.79M | $2.19M | $4.20M | $1.20M | $1.20M |
| Net PPE | $51.48M | $49.16M | $36.14M | $36.63M | $36.63M |
| -Other Intangible Assets | $1.44M | $1.61M | $1.84M | $1.99M | $1.99M |
| -Current Capital Lease Obligation | $2.48M | $2.28M | $1.60M | $2.10M | $2.10M |
| Short-Term Debt and Capital Lease Obligation | $2.48M | $2.28M | $1.60M | $2.10M | $2.10M |
| Current Accrued Expenses | $5.34M | $4.55M | $9.52M | $7.70M | $7.70M |
| -Accounts Payable | $16.55M | $13.79M | $5.64M | $5.87M | $5.87M |
| Additional Paid-In Capital | $520.51M | $516.29M | $12.11M | $9.89M | $9.89M |
| Payables | $16.55M | $13.79M | $5.64M | $5.87M | $5.87M |
| Total Current Liabilities | $33.48M | $27.96M | $24.05M | $23.73M | $23.73M |
| Total Liabilities | $74.32M | $78.12M | $364.52M | $298.95M | $298.95M |
| Other Non-Current Assets | $7.42M | $8.83M | $7.00M | $6.67M | $6.67M |
| Total Non-Current Assets | $60.34M | $59.59M | $44.98M | $45.29M | $45.29M |
| Other Current Assets | $15.36M | $15.58M | $17.43M | $13.47M | $13.47M |
| Total Current Assets | $317.69M | $331.38M | $141.47M | $94.71M | $94.71M |
| Cash and Cash Equivalents & Short-Term Investments | $226.59M | $250.05M | $64.59M | $30.00M | $30.00M |
| -Cash and Cash Equivalents | $121.53M | $132.97M | $64.59M | $30.00M | $30.00M |
| -Common Stock | $7,000.00 | $7,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Short Term Investments | $105.05M | $117.08M | – | $0.00 | $0.00 |
| Receivables | $21.61M | $20.34M | $19.52M | $12.75M | $12.75M |
| -Accounts Receivable | $21.61M | $20.34M | $19.52M | $12.75M | $12.75M |
| Inventory | $54.13M | $45.41M | $39.93M | $38.48M | $38.48M |
| -Long Term Debt | – | $9.95M | $74.97M | $9.81M | $9.81M |
| -Accumulated Depreciation | – | – | – | -$8.34M | -$8.34M |
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Tax | $94,000.00 | -$93,000.00 | $464,000.00 | $225,000.00 | $665,000.00 |
| Net Profit | -$13.34M | -$13.20M | -$21.33M | -$7.14M | -$29.82M |
| Profit from Continuing Operations | -$13.34M | -$13.20M | -$21.33M | -$7.14M | -$29.82M |
| Net Income to Parent Company | -$13.34M | -$13.20M | -$21.33M | -$7.14M | -$29.82M |
| Net Income to Common Stockholders | -$13.34M | -$13.20M | -$21.33M | -$7.14M | -$29.82M |
| Basic EPS | -$0.19 | -$0.22 | -$0.32 | -$0.11 | -$0.45 |
| Diluted EPS | -$0.19 | -$0.22 | -$0.32 | -$0.11 | -$0.45 |
| Pretax Profit | -$13.25M | -$13.29M | -$20.86M | -$6.91M | -$29.15M |
| Other Non-Operating Income (Expenses) | -$125,000.00 | -$1.41M | -$8.83M | -$46,000.00 | $421,000.00 |
| Other Income (Expense) | -$125,000.00 | -$1.41M | -$8.83M | -$46,000.00 | $421,000.00 |
| Gross Profit | $20.64M | $17.72M | $14.46M | $14.84M | $41.71M |
| Cost of Revenue | $12.90M | $11.71M | $11.58M | $10.21M | $32.51M |
| Total Operating Revenue | $33.55M | $29.43M | $26.04M | $25.05M | $74.21M |
| Total Revenue as Reported | $33.55M | $29.43M | $26.04M | $25.05M | $74.21M |
| Selling and Admin Expenses | $19.62M | $17.43M | $13.79M | $11.75M | $35.57M |
| Research & Development | $16.17M | $13.82M | $13.02M | $10.07M | $37.47M |
| Operating Profit | -$15.14M | -$13.53M | -$12.35M | -$6.98M | -$31.33M |
| Net Non-Operating Interest Income (Expense) | $2.02M | $1.65M | $316,000.00 | $112,000.00 | $1.76M |
| Non-Operating Interest Income | $2.17M | $1.88M | $539,000.00 | $334,000.00 | $2.16M |
| Non-Operating Interest Expense | $153,000.00 | $224,000.00 | $223,000.00 | $222,000.00 | $401,000.00 |
| Operating Expense | $35.78M | $31.25M | $26.80M | $21.82M | $73.04M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Financing Cash Flow | -$9.85M | $201.84M | $55.76M | $10.84M | $28,000.00 |
| -Change in Other Current Assets | $364,000.00 | -$484,000.00 | -$327,000.00 | -$746,000.00 | -$979,000.00 |
| -Change in Payables and Accrued Expense | $4.08M | $3.11M | $105,000.00 | $5.81M | $908,000.00 |
| -Change in Prepaid Assets | $214,000.00 | -$900,000.00 | -$1.96M | -$6.44M | -$2.86M |
| -Change in Inventory | -$10.21M | -$5.73M | -$1.27M | -$23.78M | -$4.93M |
| -Change in Receivables | -$1.32M | -$967,000.00 | -$6.85M | -$5.50M | -$1.76M |
| Change in Working Capital | -$7.05M | -$4.78M | -$11.39M | -$32.57M | -$10.08M |
| Other Non-Cash Items | $702,000.00 | $754,000.00 | $889,000.00 | $2.13M | $551,000.00 |
| Depreciation & Depletion & Amortization | $1.42M | $1.13M | $1.17M | $3.86M | $1.07M |
| Gain/Loss from Continuing Operations | $58,000.00 | $113,000.00 | $249,000.00 | $42,000.00 | $178,000.00 |
| Net Income from Continuing Operations | -$13.34M | -$13.20M | -$21.33M | -$29.82M | -$7.14M |
| Net cash flow from continuing operations | -$14.73M | -$11.32M | -$20.35M | -$53.61M | -$14.52M |
| -Change in Other Current Liabilities | -$183,000.00 | $184,000.00 | -$1.09M | -$1.92M | -$457,000.00 |
| Net cash flow from investing | $11.74M | -$120.80M | -$778,000.00 | $46.18M | -$2.98M |
| Net Cash Flow from Continuing Investing Activities | $11.74M | -$120.80M | -$778,000.00 | $46.18M | -$2.98M |
| Free Cash Flow | -$15.37M | -$15.07M | -$21.13M | -$59.99M | -$17.48M |
| Effect of Exchange Rate Changes | $57,000.00 | $7,000.00 | -$52,000.00 | -$172,000.00 | -$172,000.00 |
| Beginning Cash Balance | $139.22M | $69.49M | $34.91M | $31.68M | $52.55M |
| Net Change in Cash | -$12.84M | $69.72M | $34.64M | $3.40M | -$17.47M |
| Net Other Financing Charges | -$119,000.00 | -$3.93M | -$2.54M | -$657,000.00 | -$596,000.00 |
| Net Common Stock Issuance | $270,000.00 | $205.77M | $1.80M | $1.49M | $624,000.00 |
| Net Issuance Payments Of Debt | -$10.00M | $0.00 | $56.50M | $10.00M | $0.00 |
| Net Cash Flow from Continuing Financing Activities | -$9.85M | $201.84M | $55.76M | $10.84M | $28,000.00 |
| Net Investment Purchase and Sale | $12.38M | -$117.05M | $0.00 | $52.56M | -$23,000.00 |
| Net PPE Purchase and Sale | -$463,000.00 | -$3.64M | -$600,000.00 | -$5.37M | -$2.85M |
| Capital Expenditure | -$179,000.00 | -$109,000.00 | -$178,000.00 | -$1.01M | -$111,000.00 |
| Operating Cash Flow | -$14.73M | -$11.32M | -$20.35M | -$53.61M | -$14.52M |
| Ending Cash Balance | $126.44M | $139.22M | $69.49M | $34.91M | $34.91M |
| Net Preferred Stock Issuance | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on ALMR.
Sign in to join the discussion.